# Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae

> **NCT05293873** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vinmec Research Institute of Stem Cell and Gene Technology** · enrollment: 50 (actual)

## Conditions studied

- Sequelae of Injuries of Head

## Interventions

- **BIOLOGICAL:** autologous bone marrow-derived mononuclear cell transplantation
- **OTHER:** Rehabilitation therapy

## Key facts

- **NCT ID:** NCT05293873
- **Lead sponsor:** Vinmec Research Institute of Stem Cell and Gene Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293873, "Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05293873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*